Mar 2026 • PharmaTimes Magazine • 9
// CONDITIONS //
IBSA launches Perovial for the treatment of acute Peyronie’s disease
IBSA UK&I has announced the launch of Perovial, a treatment for the management of acute Peyronie’s disease (PD).
PD is a chronic, progressive condition caused by the formation of plaque in the tunica albuginea. Characteristic symptoms include penile curvature, deformity, pain and erectile dysfunction. It is estimated that between 0.3% and 13.1% of men worldwide live with PD, but underdiagnosis, symptom delay and embarrassment mean that the true number is likely to be higher.
Approximately 60% of men with Peyronie’s disease see the disease negatively impact their quality of life. Early recognition of symptoms is vital, since, once the disease reaches the acute phase, treatment options are limited. Intervention during the acute phase could, however, inhibit the progression of scarring and deformity from the disease.
Perovial is the first ever hyaluronic acid injectable treatment to be licensed in this indication. It is delivered via injection over 10 to 12 weeks of treatment, and the hyaluronic acid it contains is intended to soften plaque and encourage the remodelling of tissue.
Clinical trials of Perovial have demonstrated improvements in plaque size, penile curvature and erectile function, as well as a tolerable safety profile.
EURneffy receives positive opinion for anaphylaxis treatment in children
ALK has announced that its EURneffy 1mg nasal adrenaline spray has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for emergency anaphylaxis treatment in children aged four years and older with a bodyweight between 15 and 30kg.
Anaphylaxis is the most serious type of allergic reaction, occurring in one to 761 in every 100,000 children each year in Europe. It is more common in boys. Food allergies account for over two-thirds of anaphylaxis cases, with food allergy-related hospitalisations on the rise.
The CHMP’s positive opinion of EURneffy encompasses anaphylaxis caused by insect stings and bites, foods, medications and other common allergens.
The European Commission (EC) previously granted marketing authorisation in September 2024 to EURneffy 2mg, for the treatment of anaphylaxis in adults and children weighing more than 30kg.
EURneffy has been found to be rapidly absorbed, and to perform as well as traditional injectable forms of anaphylaxis treatment. It also has a favourable tolerability and safety profile.
The positive opinion expressed by the CHMP will be reviewed by the EC with a view to authorisation of EURneffy 1mg. The authorisation, if granted, would apply to all EU member states and Iceland, Liechtenstein and Norway.
ErVimmune has announced a total of 17m euros in new funding, allowing it to advance its cancer vaccine candidate.
The company’s lead candidate, ErVac01, is a heterologous vaccine formulation containing a collection of human endogenous retrovirus-derived epitopes, designed to cover the majority of the worldwide population in terms of HLA alleles.
Otsuka has announced that its Dawnzera (donidalorsen) has received approval from the European Commission (EC) for the prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older.
Around half of HAE patients first experience symptoms before the age of ten. The majority of patients also experience their first HAE attack before reaching adulthood.
En Carta Diagnostics, a start-up company developing molecular diagnostics kits, has announced that its EC Pocket Lyme test has received Breakthrough Device Designation from the US FDA.
The goal of EC Pocket Lyme is to detect Borrelia bacteria in interstitial fluid samples taken from the skin of people with signs of tick bites or erythema migrans.
Kahimmune Therapeutics has entered an exclusive licensing agreement with Gustave Roussy and Société d’Accélération du Transfert de Technologies Paris-Saclay. Kahimmune was created in late 2025, building on immunology discoveries related to the dark genome, which has lately been seeing more study. The licensing agreement grants Kahimmune exclusive licence to the technology behind its Kahinomics platform, as well as the neoantigens – known as Kahigens – produced by the platform.
Responding to the publication of a Mumsnet survey alongside the Future Minds report on transforming young people’s mental health, Rebecca Gray, from the NHS Confederation, said:
“Anxiety in childhood often persists into adolescence and is linked to developing depression in later life. Early intervention can change the trajectory of children’s lives by preventing problems from becoming more serious."
Resident doctors in England have voted decisively to continue industrial action for a further six months, extending one of the most prolonged disputes the NHS has faced in recent years. The British Medical Association confirmed that 93% of those who voted backed renewed strike action, reflecting deep frustration over pay erosion and a shortage of training posts.
PharmaTimes
PharmaTimes is the UK’s leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative and trustworthy content through impartial, balanced and informed opinion and analysis.